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Background: Serotype-specific antibody responses to unconjugated pneumococcal 
polysaccharide vaccine (PPV) evaluated by a World Health Organization (WHO)-
standardized enzyme-linked immunosorbent assay (ELISA) are the gold standard for 
diagnosis of specific polysaccharide antibody deficiency (SAD). The American Academy 
of Allergy, Asthma and Immunology (AAAAI) has proposed guidelines to interpret the PPV 
response measured by ELISA, but these are based on limited evidence. Additionally, 
ELISA is costly and labor-intensive. Measurement of antibody response to Salmonella 
typhi (S. typhi) Vi vaccine and serum allohemagglutinins (AHA) have been suggested as 
alternatives. However, there are no large cohort studies and cutoff values are lacking.
Objective: To establish cutoff values for antipneumococcal polysaccharide antibody 
response, anti-S. typhi Vi antibody, and AHA.
Methods: One hundred healthy subjects (10–55 years) were vaccinated with PPV and 
S. typhi Vi vaccine. Blood samples were obtained prior to and 3–4 weeks after vacci-
nation. Polysaccharide responses to 3 serotypes were measured by WHO ELISA and 
to 12 serotypes by an in-house bead-based multiplex assay. Anti-S. typhi Vi IgG were 
measured with a commercial ELISA kit. AHA were measured by agglutination method.
results: Applying AAAAI criteria, 30% of healthy subjects had a SAD. Using sero-
type-specific fifth percentile (p5) cutoff values for postvaccination IgG and fold increase 
pre- over postvaccination, only 4% of subjects had SAD. One-sided 95% prediction 
intervals for anti-S. typhi Vi postvaccination IgG (≥11.2 U/ml) and fold increase (≥2) were 
established. Eight percent had a response to S. typhi Vi vaccine below these cutoffs. 
AHA titer p5 cutoffs were ½ for anti-B and ¼ for anti-A.
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conclusion: We establish reference cutoff values for interpretation of PPV response 
measured by bead-based assay, cutoff values for S. typhi Vi vaccine responses, and 
normal values for AHA. For the first time, the intraindividual consistency of all three 
methods is studied in a large cohort.
Keywords: polysaccharide antibody deficiency, specific antibody deficiency, pneumococcal polysaccharide 
vaccine, Salmonella typhi Vi vaccine, allohemagglutinins
inTrODUcTiOn
Vaccine responses to polysaccharide vaccines are important for 
the diagnosis and management of patients with suspected primary 
immunodeficiencies (PID) (1). Several genetically defined PIDs 
are associated with a specific polysaccharide antibody deficiency 
(SAD), for example, Wiskott–Aldrich Syndrome, ataxia telan-
giectasia, 22q11.2 deletion, NEMO deficiency, and autosomal 
dominant hyper-IgE syndrome (2). Furthermore, responses to 
polysaccharides can be impaired in patients with IgG subclass 
deficiency, selective IgM deficiency, selective IgA deficiency, and 
asplenia (2). A diagnosis of SAD is made when there is an iso-
lated defect of the pneumococcal polysaccharide response with 
normal responses to protein and conjugate vaccines and normal 
immunoglobulin levels (3). Patients with SAD suffer from recur-
rent bacterial respiratory tract infections, such as sinusitis, otitis 
with chronic otorrhea, bronchitis, or pneumonia. SAD is found 
in 12–27% of children investigated for recurrent respiratory tract 
infections (4–8). Patients with increased susceptibility to infec-
tions and deficient polysaccharide response can be treated with 
prophylactic antibiotics, immunoglobulin replacement therapy, 
or both.
Response to non-conjugated pneumococcal polysaccharide 
vaccine (PPV), assessed by a World Health Organization (WHO)-
standardized Enzyme-Linked Immunosorbent Assay (ELISA), 
is the gold standard for evaluating T-independent responses (9). 
Serotype-specific IgG are measured before and after vaccination 
with PPV. The consensus statement of the American Academy 
of Allergy, Asthma and Immunology (AAAAI) on diagnostic 
vaccination defines a normal polysaccharide antibody response 
in patients above 18 months old as (i) a postvaccination serotype-
specific IgG concentration equal to or greater than 1.3 µg/ml and 
(ii) a twofold increase of the postvaccination concentration when 
compared to the pre-vaccination concentration (unless pre-vacci-
nation IgG > 4 µg/ml). Children under age 6 years should achieve 
these cutoffs for at least 50% of serotypes tested, individuals 6 years 
and older for 70% of tested serotypes. Although these criteria are 
now widely adopted among PID experts, cutoffs are arbitrary and 
based on limited evidence due to historical changes and perfec-
tion of the specific antibody detection method (radio-immuno-
assay to ELISA, addition of cell wall polysaccharide, and 22F) 
(9, 10). Immunological memory for pneumococcal polysac-
charides can be found in most individuals following previous 
infection or nasopharyngeal carriage. Since the introduction of 
the conjugated pneumococcal vaccine for routine immunization 
of children, in most industrialized countries, even more individu-
als have been primed with conjugated polysaccharides (11, 12). 
Therefore, the measurement of pneumococcal polysaccharide 
antibodies may no longer be the preferable assessment of the 
T-independent response (13). Other limitations include cost, 
workload, and concerns about hyporesponsiveness to polysac-
charide vaccines with subsequent administrations (14).
To overcome difficulties with the PPV, two alternative strate-
gies for evaluating the polysaccharide response in patients with 
suspected PID have been proposed: quantification of Salmonella 
typhi Vi vaccine response or allohemagglutinins (AHA), formerly 
named isohemagglutinins. Yet, none of these alternatives has 
been studied against the gold standard in a large control popula-
tion, and reference values are lacking.
Salmonella typhi (S. typhi) Vi vaccine (Typhim Vi™, Sanofi 
Pasteur MSD) is a potential alternative polysaccharide vaccine for 
evaluating the polysaccharide response in patients with suspected 
PID. S. typhi Vi vaccine contains purified Vi capsular polysac-
charide of S. typhi, to which the specific antibody response can 
reliably be measured by ELISA (15, 16). Seroconversion rates 
were described in two small healthy cohorts [N =  26 (15) and 
N = 16 (16)]; the results were not compared to the gold standard 
pneumococcal antibody assay.
Measurement of AHA is widely adopted as an alternative 
measurement of polysaccharide responses (9, 12, 17–19). AHA 
are antibodies reactive to the A or B polysaccharide antigens on 
erythrocytes. Surprisingly, despite their universal utilization in 
diagnosis, there were no data on the diagnostic value of AHA 
for SAD, only anecdotal reports of low or absent AHA in PID. 
We have recently conducted a retrospective study in patients 
with suspected PID and found a low diagnostic value of AHA 
to predict a SAD (20). Data on normal values of AHA in healthy 
individuals, using current detection methods with differentiation 
of IgM and IgG, are lacking.
The aim of this study was to establish cutoff values for antip-
neumococcal polysaccharide, anti-S. typhi Vi antibody, and AHA 
responses.
MaTerials anD MeThODs
study Design
We conducted a prospective cohort study in 100 healthy volunteers. 
The study was approved by the Ethics committee of University 
Hospitals Leuven, Belgium. Volunteers aged 2–55  years were 
included when they did not meet any of the following exclusion 
criteria: (i) previous vaccination with an unconjugated polysac-
charide salmonella vaccine or pneumococcal vaccine within 
5 years prior to study participation, (ii) previous allergic reaction 
to any vaccine, and (iii) medical history suggestive of PID. After 
obtaining full informed and written consent, a blood sample was 
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drawn for pre-vaccination serum, allohemagglutinins (AHA), 
and blood group. Typhim Vi™ (Sanofi Pasteur, Lyon, France) 
and Pneumovax 23™ (Merck Sharp en Dohme B.V., Haarlem, 
the Netherlands) vaccines were administered by intramuscular 
injection at two distinct sites (right and left deltoid muscle). 
Information on the clinical history and potential previous con-
tact with S. typhi was obtained by a medical doctor and noted 
in a case report form. Three to four weeks after vaccination, a 
second blood sample was obtained for postvaccination antibody 
concentrations. Pre- and postvaccination blood was separated by 
centrifugation and serum was stored at −20°C until simultaneous 
analysis of specific IgG.
antibody response to PPV
Antipneumococcal polysaccharide IgG against three serotypes 
that are not in the conjugated vaccine, 8, 9N and 15B, were 
measured by the third-generation WHO ELISA, incorporating 
adsorption of samples with cell wall polysaccharide and capsular 
polysaccharide 22F (20). We have previously demonstrated high 
precision of the ELISA assay in our laboratory (11, 21). Antibody 
measurement of specific antipneumococcal IgG antibodies to 
serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F (sero-
types included in both 13-valent conjugated pneumococcal vac-
cine and PPV) was performed at the Statens Serum Institute using 
an in-house Luminex bead-based assay. This method permits the 
simultaneous measurement of all 12 serotype-specific IgG in a 
single well. Briefly, pneumococcal polysaccharides purchased 
from LGC Standards (American Type Culture Collection, VA, 
USA) or from SSI Diagnostica (Hilleroed, Denmark) were conju-
gated to poly-l-lysine and then covalently bound to carboxylated 
microspheres (Luminex, TX, USA). Serum samples (and the 89SF 
standard) were pre-adsorped in adsorbance buffer containing 
CWPS Multi (SSI Diagnostica, Hilleroed, Denmark) and then 
incubated with the conjugated microspheres, followed by incuba-
tion with R-phycoerythrin conjugated anti-human IgG (Jackson 
ImmunoResearch laboratories, West Grove, PA, USA). Finally, 
the microspheres were read on a Bio-Plex 200 system (Bio-Rad, 
Hercules, CA, USA). Data were acquired using Bio-Plex Manager 
5.0 (Bio-Rad Hercules, CA, USA). Pneumococcal polysaccharide 
serum calibrated to the FDA 89SF reference serum was used as a 
reference (22). Serum IgG concentrations were calculated using 
a standard curve of median fluorescent intensity (MFI) against 
expected IgG concentration for FDA 89-SF and converted to 
micrograms per milliliter. Pre- and postimmunization samples 
were analyzed on the same plate. Each sample was analyzed in 
duplicate, and analysis was repeated if the coefficient of variation 
between duplicates was above 10%.
antibody response to S. typhi Vi Vaccine
Specific antibodies to S. typhi Vi vaccine were measured using 
a commercially available ELISA kit (VaccZyme™ Anti-S. typhi 
Vi human IgG EIA kit from The Binding Site Group Ltd., 
Birmingham, UK). Samples, standards, and quality controls were 
run in duplicate following the manufacturer instructions. Pre- 
and postvaccination samples were analyzed on a single plate in a 
single run. The results were expressed as units per milliliter (range 
7.4–600 U/ml). Samples resulting in a value below the lower limit 
of detection (<7.4 U/ml) were set to 3.7 U/ml. Values above the 
upper limit of detection (600 U/ml) are reported as 600 U/ml.
Detection of aha
Blood group and AHA were determined on pre-vaccination 
EDTA blood samples from all subjects. Anti-A and anti-B IgG 
and IgM (AHA) were determined by the immunohematology 
laboratory of the Red Cross Flanders, using column agglutination 
technology (Bio-Rad®) with LISS Coombs columns and neutral 
columns, respectively, as previously described (20).
statistical analysis
Statistical calculations were performed using Graphpad Prism 
version 7.0 for Mac OS X (Graphpad software, La Jolla, CA, 
USA). Since only low antibody levels are clinically relevant for 
disease, the lower fifth percentile value (p5) or the one-sided 
95% prediction interval (PI) were calculated and used as cutoffs. 
For antipneumococcal IgG, fold increase of antipneumococ-
cal polysaccharide antibodies and AHA p5 were determined. 
For anti-S. typhi Vi IgG and fold increase of anti-S. typhi Vi 
antibodies, geometric mean and the one-sided 95% prediction 
interval (PI) were derived from the log-transformed data. The 
following formula was applied on the log-transformed results: 
95 10 95 1% . ,PI mean SD= −
+
−t
n
nn . t0.95,n −  1 is the 95% quantile of 
a Student’s t distribution with n − 1 degrees of freedom. N is the 
sample size. Geometric mean and 95% PI were then derived by 
exponentiating the log-derived mean and 95% PI.
resUlTs
study Population
Forty-three males and 57 females were included, aged 10–55 years 
(median 25 years, IQR 23–30 years). All subjects were of Caucasian 
descent except for one female of Ethiopian origin. Ten subjects 
were aged below 19 years, and 6 subjects were aged above 49 years 
(Figure S1 in Supplementary Material). The median interval 
between the vaccination and postvaccination blood sample was 
24 days (IQR 21–28 days).
None of the subjects had been vaccinated with pneumococcal 
conjugated vaccine. Five included subjects had previously been 
vaccinated with S. typhi polysaccharide vaccine (≥9 years prior 
to study participation). None of the subjects noted a known his-
tory of S. typhi infection. Three subjects had lived in an endemic 
S. typhi area for 1  month or longer (1  month, 3  months, and 
6 years).
Two subjects reported one episode of pneumonia in the 
past 5 years. None declared to suffer from chronic lung disease. 
Number of upper respiratory tract infections in the last year was 
reported to be 0 or 1, 2–3, 4–5 or >5 in 72, 24, 3, and 1 subject, 
respectively. A lifelong history of more than one episode of pro-
longed otorrhea (>10 days) was reported in three subjects. None 
of the included subjects had experienced invasive infections. 
Tooth abscess and appendicitis were mentioned in two and three 
individuals, respectively.
No serious or severe vaccine-related adverse events were 
reported. Minor adverse events included fever (n  =  3), local 
TaBle 1 | number of subjects classified with specific polysaccharide 
antibody deficiency among 100 healthy volunteers for each test 
method separately (elisa or bead-based assay) and for all serotypes 
in total, according to the applied interpretation method: (a) american 
academy of allergy, asthma and immunology (aaaai) criteria (normal 
response is postvaccination igg ≥ 1.3 µg/ml and ≥2-fold increase 
for at least 67% of serotypes) or (B) calculated fifth percentile (p5) 
cutoffs for postvaccination igg and fold increase (normal response 
is postvaccination igg ≥ serotype-specific p5 value and fold 
increase ≥ serotype-specific p5 value for at least 67% of serotypes).
elisa 
serotypes 
only  
(8, 9n, 15B)
Bead-based assay 
serotypes only (1, 3, 4, 5, 
6B, 7 F, 9 V, 14, 18c, 19 a, 
19 F, 23 F)
all 
serotypes
AAAAI criteria 
applied
11 34 30
p5 cutoffs applied 2 4 4
AAAAI and p5 
cutoffs
2 4 4
4
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redness at the site of PPV injection (n = 6), local redness at the 
site of S. typhi Vi vaccine injection (n = 1), and local tenderness.
Pneumococcal Polysaccharide antibody 
response
Paired pre- and postvaccination anti-polysaccharide IgG against 
serotypes 8, 9, and 15B, measured by ELISA, and pre-vaccination 
IgG levels against fold-increase are shown in Figure S2 in 
Supplementary Material. Using the AAAAI guidelines for SAD, 
3 subjects responded to 0/3 ELISA-tested serotypes, 8 responded 
to 1/3 serotypes, 32 to 2/3, and 57 to 3/3 serotypes. When a 
response above the cutoffs for 67% (2/3) of serotypes is accepted 
as an adequate response, 11/100 healthy subjects would have a 
SAD (Table 1). When applied to all 15 serotypes, including those 
assessed by bead-based assay, 30/100 subjects respond to <10/15 
serotypes and would have a SAD (Table 1). The median number 
of serotypes with adequate response was 11 (IQR 9–13).
As can be seen from Figure 1, a 1.3-µg/ml cutoff for postvac-
cination IgG and a twofold increase are too high as thresholds 
for some less immunogenic serotypes, when measured by bead-
based assay. We, therefore, determined serotype-specific cutoffs. 
D’Agostino and Pearson normality test showed that the results 
were not normally distributed. A normal distribution was found 
for postvaccination IgG and fold increase for some serotypes 
when log-transformed, but not for all (log-transformed postvac-
cination IgG normally distributed for serotypes 8, 9N, 1, 4, 7F, 14, 
and 23F; log-transformed fold increase normally distributed for 
serotypes 8, 9N, 15B, 1, 4, 5, 7F, 9V, 14, and 18C). Since only low 
values for antibody response are of clinical significance, p5 for 
postvaccination IgG in the cohort was determined to establish 
cutoff values for the healthy population (Table 2). To determine 
the fold increase median and p5, subjects with a pre-vaccination 
IgG level >4  μg/ml were excluded, because fold increase 
decreases with increasing pre-vaccination titers and a >2-fold 
increase becomes unlikely above this IgG level (23). Five percent 
of the healthy volunteers showed no increase in antibody titer for 
serotypes 15B, 3, 6B, and 19A (Table 2). A p5 of twofold was only 
found for serotype 14. For all other serotypes, the p5 cutoff for 
fold increase was between one and two.
Next, we redetermined the number of subjects with a SAD, 
defining a normal response as postvaccination IgG ≥ serotypes-
specific p5 and fold increase ≥p5 for at least 67% of serotypes. 
Again, when pre-vaccination concentration was above 4 µl/ml, 
no threshold was used for fold increase. Using these criteria, 
only 2/100 subjects are classified with a SAD when only taking 
into account the ELISA serotypes and 4/100 subjects when only 
considering the bead-based assay results (Table 1).
S. typhi Vi Vaccine antibody response
Paired pre- and postvaccination specific antibody levels are shown 
in Figure S3 in Supplementary Material. Pre-vaccination, 73/100 
subjects had anti-S. typhi Vi IgG below the detection limit of the 
ELISA kit (7.4 U/ml). Figure S4 in Supplementary Material sets 
pre-vaccination IgG levels against fold increase. Three subjects 
had a pre-vaccination anti-S. typhi Vi IgG level above 100 U/ml: 
one had previously been vaccinated and one had been living 
in Ethiopia for 6  years. Median, p5, geometric mean and one-
sided 95% PI for postvaccination anti-S. typhi Vi IgG, and fold 
increase can be found in Table 3. Since the data were log-normal 
distributed, we propose to use the 95% PI as cutoff for normal 
values for postvaccination IgG (≥11.2 U/ml) and fold increase 
(≥2). Sub-analyses in the cohort aged 10–18 and 50–55  years 
showed comparable 95% PI values. Only 33% of subjects with a 
pre-vaccination anti-S. typhi Vi IgG level above 100 U/ml, were 
able to mount a twofold increase. When a normal response to 
S. typhi Vi vaccine is defined as postvaccination anti-S. typhi Vi 
IgG ≥11.2 U/ml and a fold increase ≥2 (unless pre-vaccination 
titer ≥100  U/ml), 8/100 healthy volunteers have an abnormal 
response to S. typhi Vi polysaccharide. Four among these eight 
with abnormal response had pre-vaccination titer above the 
detection limit and history of exposure (vaccination) was present 
in two out of four. Three out of five with history of previous 
vaccination showed an adequate response, despite detectable 
anti-S. typhi Vi IgG pre-vaccination.
allohemagglutinins
Two subjects had no AHA because they had blood group AB. 
Blood group A was found in 42 subjects, blood group B in 11, 
and blood group O in 45. Therefore, anti-A could be detected in 
56 subjects with blood group B or O, and anti-B in 87 subjects 
with blood group A or O. AHA titers are summarized in Table 4 
and Figure S5. When AHA at or above p5 are considered normal, 
abnormal AHA can be defined as anti-B (IgM or IgG) below ½ 
or anti-A (IgM or IgG) below ¼. None of the subjects had all 
AHA below p5. Five subjects had one (n = 4) or two (n = 1) titers 
below p5.
intraindividual correlation of 
Polysaccharide response Tests
Next, we assessed whether low pneumococcal polysaccharide 
response corresponded to low Vi polysaccharide response and 
low response to blood group polysaccharides within one indi-
vidual. Figure 2 shows the number of individuals with abnormal 
FigUre 1 | Polysaccharide-specific igg levels postvaccination (a) and fold increase (B) of polysaccharide-specific antibody concentration 
3–4 weeks after vaccination with pneumococcal polysaccharide vaccine. Horizontal bars indicate medians; red dashed lines indicate fifth percentile values. 
The 1.3-µg/ml cutoff and twofold increase cutoff, as advised by the American Academy of Allergy, Asthma and Immunology guidelines, are drawn in dotted lines and 
area below the cutoff is filled in gray.
TaBle 2 | serotype-specific igg and fold increase 3–4 weeks postvaccination with pneumococcal polysaccharide vaccine.
serotype Postvaccination igg (μg/ml) Fold increase
Median Q1 Q3 p5 Median Q1 Q3 p5
Enzyme-linked immunosorbent assay 8 5.7 3.7 9.7 1.8 5.2 3.4 9.4 1.4
9N 4.5 2.6 10.1 1.2 3.7 2.1 6.2 1.1
15B 7.2 3.5 17.2 2.0 2.4 1.4 4.5 1.0
Bead-based assay 1 17.0 5.1 64.7 1.4 20.3 6.9 34.2 1.8
3 0.6 0.2 1.2 0.1 2.7 1.6 6.1 1.0
4 1.5 0.7 4.8 0.2 7.4 3.2 15.1 1.2
5 1.4 0.5 5.2 0.1 6.6 2.8 13.6 1.5
6B 1.3 0.3 3.4 0.1 4.0 2.1 13.7 1.0
7F 16.1 6.7 41.8 1.1 12.4 5.6 26.3 1.8
9V 4.6 1.9 17.1 0.6 6.5 2.5 14.4 1.2
14 19.8 2.8 41.3 0.6 17.2 4.8 43.3 2.0
18C 3.8 1.0 15.8 0.3 6.4 3.0 14.9 1.4
19A 6.4 1.8 29.4 0.7 2.2 1.7 7.3 1.0
19F 7.3 2.2 33.9 1.2 2.8 1.6 7.2 1.1
23F 5.4 2.0 20.0 0.3 6.2 2.7 14.0 1.1
Q1, 25th percentile (quartile 1); Q3, 75th percentile (quartile 3); p5, fifth percentile.
5
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FigUre 2 | Venn diagram showing the subjects (black dots) with abnormal antibody response for each detection method among 100 healthy 
subjects, when the calculated fifth percentile cutoff values are used. The subjects with abnormal results for more than one test are found in the intersections. 
Subjects with normal results on all tests are not shown. Where present, the relevant clinical history is indicated by the arrows. URTI, upper respiratory tract 
infections; yo, years old.
TaBle 4 | allohemagglutinins in 98 healthy subjects with blood group a 
(n = 42), B (n = 11), or O (n = 45).
Median iQr Minimum Maximum p5
Anti-B IgG (n = 87) 16 8–64 1 2048 2
Anti-B IgM (n = 87) 32 8–64 2 2048 2
Anti-A IgG (n = 56) 64 20–256 1 2048 4
Anti-B IgM (n = 56) 64 16–128 2 512 4
IQR, interquartile range; p5, fifth percentile.
TaBle 3 | anti-Salmonella typhi Vi igg and fold increase 3–4 weeks 
postvaccination with S. typhi Vi vaccine.
n = 100 Median iQr p5 geometric 
mean
One-sided 
a95% Pi
Postvaccination  
anti-S. typhi  
Vi IgG (U/ml)
71.5 36.8–148.7 10.3 72.2 11.2a
Fold increase 15 6–24 1 12 2a
IQR, interquartile range; p5, fifth percentile; PI, prediction interval.
aProposed normal S. typhi Vi vaccine response.
6
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test results for these three different test methods of polysaccha-
ride response. Detailed results of all 15 subjects with one or more 
abnormal test result are shown in Table S1 in Supplementary 
Material. An abnormal test result is defined as a response below 
the p5 as described above. None of the control subjects had an 
abnormal response in all three tests. Only two out of eight of 
controls with a defective S. typhi Vi vaccine response had a defect 
in the response to PPV.
DiscUssiOn
In this study, we established cutoff values for an adequate response 
to S. typhi Vi vaccine and AHA (IgG and IgM) in the largest 
healthy population reported to date (n = 100). To determine the 
significance of inadequate S. typhi Vi vaccine response and low 
AHA, we compared these polysaccharide responses to the current 
gold standard: pneumococcal antibody response to PPV.
The WHO ELISA antipneumococcal polysaccharide IgG nor-
mal values remain a matter of debate. Applying the AAAAI expert 
guidelines for SAD diagnosis to the three ELISA-tested serotypes, 
we found 11% of the cohort had an inadequate response. Applying 
the AAAAI guidelines to the 15 serotypes (12 bead-based assay 
tested), we found 30% of the cohort had an inadequate response. 
In contrast, when the fifth percentile values were used as cutoffs, 
only 4% had an inadequate response. Although the AAAAI 
threshold for postvaccination IgG of 1.3 µg/ml was in the range 
of p5 for the ELISA-tested serotypes, for bead-based assay tested 
serotypes the p5 was below 1  µg/ml for 9/12 serotypes. Our 
group has previously suggested using serotype-specific p5 cutoffs 
for postvaccination IgG for ELISA as well as bead-based assay 
(21, 24). The AAAAI criteria are derived from ELISA data. Previous 
studies have shown a good correlation of ELISA with bead-based 
assay results but the absolute antibody concentrations are not the 
same. Also, this was not the case for all serotypes (e.g., serotype 3) 
and correlations were poorer in non-vaccinated subjects and 
infants (24–28). For fold increase, a p5 of about two is attained 
for only three bead-assay tested serotypes and for none of the 
ELISA-tested serotypes. Fifth percentile cutoffs for fold increase 
have never been published but our findings are consistent with a 
meta-analysis of older studies and our earlier xMAP study, which 
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showed that a proportion of healthy subjects do not mount a 
twofold increase, and this proportion is serotype and age depend-
ent (29, 30). Based on these studies and our present findings, 
we advise to use method- and serotype-specific cutoffs for fold 
increase as well as postvaccination IgG. Therefore, the proposed 
p5 cutoffs were used in this study to compare PPV response and 
S. typhi Vi vaccine response within one individual.
We have tested S. typhi Vi response in 100 healthy individuals and 
defined p5 for postvaccination anti-S. typhi Vi IgG (<11.2 U/ml) 
and fold increase (<two-fold) as cutoff for diagnosis of SAD. We, 
thereby, addressed three major limitations of previous studies 
describing S. typhi Vi antibody responses: limited number of 
healthy individuals studied (15, 16), use of an in-house hence not 
widely available ELISA (15), radio-immuno assay (31), or bead-
based assay (32) for detection of anti-S. typhi Vi antibodies and 
restricted age groups [in children 2–16 years (33) or 2–5 years 
(34) old]. A comparison of pneumococcal polysaccharide 
antibody response and S. typhi Vi vaccine response was recently 
conducted in 16 healthy volunteers, 22 common variable immu-
nodeficiency patients, and 27 hypogammaglobulinemic patients 
and showed superiority of anti-S. typhi Vi vaccine responses to 
discriminate between groups. However, pneumococcal response 
was assessed by a commercial PPV-coated ELISA and these 
ELISAs, measuring a combined IgG response, have limited value 
to diagnose patients with SAD (13). Using the same commercial 
ELISA kit for S. typhi Vi vaccine, Sánchez-Ramón and colleagues 
found a minimum postvaccination IgG concentration of 32 and 
7.4 U/ml and minimum fold increase of 3.4 and 1 in a healthy and 
Common Variable Immunodeficiency group, respectively, which 
shows that our proposed criteria discriminate healthy subjects 
from SAD subjects (16). Ferry et al. found a greater than threefold 
increase in 95% of 23 healthy vaccinated individuals, using an 
in-house ELISA (15).
As expected in an industrialized country, most of the subjects 
had undetectable anti-S. typhi Vi IgG pre-vaccination (73%). This 
is a major advantage of S. typhi Vi vaccine for the evaluation of 
polysaccharide responsiveness, although it impedes calculation of 
a fold increase. We have tackled this issue by assigning a value of 
half the lower detection limit to these subjects. When using the 
threshold for fold increase as proposed here, the same method 
will have to be applied. Another difficulty is to define above which 
pre-vaccination anti-S. typhi Vi IgG level this increase should not 
be expected. A study with PPV has shown a very low likelihood 
of increase of specific antibody concentrations at given pre-vacci-
nation concentrations. These concentrations are serotype-specific 
(23). To our knowledge, a similar study has not been conducted 
for S. typhi Vi vaccine. We have arbitrarily chosen 100 U/ml as 
a threshold for high pre-vaccination antibody concentration. 
Further studies are needed to determine whether this threshold is 
correct and needed at all. The inclusion of subjects with a history of 
S. typhi Vi vaccination and subjects who have lived in endemic area 
has revealed some interesting findings. Although only 6 subjects 
had a definite encounter with Vi antigen in the past, 27 subjects 
showed detectable pre-vaccination anti-S. typhi Vi antibodies. Half 
of the subjects with S. typhi Vi vaccine response below our pro-
posed criteria had pre-vaccination antibodies, two of them with 
a history of S. typhi Vi vaccination, demonstrating that previous 
vaccination probably impedes the use of these criteria or this test 
to assess polysaccharide responsiveness. This hyporesponsiveness, 
i.e., lower response to subsequent vaccinations with a polysac-
charide vaccine, has been described for the pneumococcal and 
meningococcal polysaccharide vaccines as well (35).
Allohemagglutinins are used by many PID experts and advised 
by the AAAAI guidelines to assess polysaccharide antibody 
response, although reference values have been lacking. We have 
previously found low sensitivity and specificity of AHA titers in 
the diagnosis of a SAD in 180 subjects with suspected humoral 
immunodeficiency (20). In the current study, we found a large 
range of AHA titers in healthy subjects with p5 cutoffs as low as 
½ for anti-B and ¼ for anti-A. These thresholds are much lower 
than the cutoffs currently used (1/8 for both below the age of 
3 years and 1/16 above 3 years). We found no association of low 
AHA with low S. typhi Vi vaccine or PPV response. Therefore, 
these data further question the clinical value of AHA in the 
diagnosis of SAD. AHA are generated in response to gut bacteria 
and cross-react with AB blood group antigens (36, 37). Absence 
of AHA may, therefore, reflect either inability to generate polysac-
charide antibodies (in patients) or differences in gut microbiome 
(in healthy individuals).
This is the first study to compare serotype-specific pneumo-
coccal polysaccharide antibody response with S. typhi Vi vaccine 
response and AHA. We found an overlap of inadequate vaccine 
response in two subjects. Remarkably, one of these subjects had 
low AHA and had a history of prolonged otorrhea, a clinical sign 
that has been shown to be most predictive of SAD in patients 
with recurrent respiratory tract infections (5). The presence of 
undiagnosed SAD in this subject is possible. All other subjects 
with either low PPV response, low S. typhi Vi vaccine response, 
or both, had no or very little (only one pneumonia) clinical signs 
suggestive of SAD. A partially impaired polysaccharide response 
may lead to adequate responses to some polysaccharides and an 
inadequate response to others, without increased susceptibility to 
infection with encapsulated bacteria. Measuring the response to a 
single polysaccharide as with the S. typhi Vi assay may, therefore, 
lead to false positive and false negative results. Application of the 
established cutoff values in patients with suspected antibody defi-
ciency will teach us further whether S. typhi Vi vaccine response 
is a valuable alternative or an additional tool for the diagnosis 
of SAD. A follow-up study in 100 individuals with suspected 
humoral immunodeficiency is currently under analysis.
There are also limitations to this study. To cross-validate the two 
methods to detect antipneumococcal polysaccharide antibodies, 
ELISA and bead-based assay, the same serotypes should have been 
tested with both methods. Ideally, only response to non-PCV 
serotype should be measured, although this is of less importance 
in this cohort of non-PCV-vaccinated subjects. Additionally, using 
only three serotypes to define a normal or abnormal response is 
probably not optimal, especially because of the 50/70% rule on 
number of serotypes needed with an adequate response.
In conclusion, this is the largest study to date establishing 
normal values for postvaccination IgG and fold increase of 
IgG postvaccination with S. typhi Vi vaccine, measured with 
a commercially available ELISA kit. We confirmed that the 
AAAAI criteria on pneumococcal polysaccharide response for 
8Schaballie et al. Antipneumococcal, Anti-Salmonella IgG and AHA
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 546
diagnosis of SAD cannot be applied to bead-based assay results, 
and that a twofold increase is not attained in many healthy 
individuals for serotypes tested with ELISA. Instead, we propose 
to use method- and serotype-specific p5 cutoff values from a 
healthy population, as we have established with this study. This 
report confirms our earlier findings that the specificity of AHA 
for the detection of SAD is low. The established cutoff values 
will allow clinical validation of the S. typhi Vi assay and PPV 
response measured by bead-based assay to diagnose SAD in a 
patient population.
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